Tuberculosis is still an essential concern in underdeveloped or developing countries worldwide when treating psoriasis patients with biologics, and the risk is even higher with TNF inhibitors than with any other biologic class.26, 27 Therefore, anti-TNFs opted for specific groups of psoriasis patients, such as those having concomitant inflammatory bowel disease.27 This evidence concerns the gene TNF and psoriasis.